Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma

Objective: This study was performed to identify clinical predictors for better survival in patients with advanced hepatocellular carcinoma (HCC) under sorafenib treatment. Methods: Between December 2007 and January 2010, 46 patients with advanced HCC were treated with sorafenib until significant tum...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Koschny, Ronald (VerfasserIn) , Gotthardt, Daniel (VerfasserIn) , Jäger, Dirk (VerfasserIn) , Stremmel, Wolfgang (VerfasserIn) , Ganten, Tom M. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2013
In: Oncology
Year: 2013, Jahrgang: 84, Heft: 1, Pages: 6-13
ISSN:1423-0232
DOI:10.1159/000342425
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1159/000342425
Verlag, Volltext: https://www.karger.com/Article/FullText/342425
Volltext
Verfasserangaben:Ronald Koschny, Daniel Gotthardt, Christiane Koehler, Dirk Jaeger, Wolfgang Stremmel and Tom M. Ganten

MARC

LEADER 00000caa a2200000 c 4500
001 158386959X
003 DE-627
005 20220815061226.0
007 cr uuu---uuuuu
008 181120s2013 xx |||||o 00| ||eng c
024 7 |a 10.1159/000342425  |2 doi 
035 |a (DE-627)158386959X 
035 |a (DE-576)51386959X 
035 |a (DE-599)BSZ51386959X 
035 |a (OCoLC)1341023767 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Koschny, Ronald  |d 1974-  |e VerfasserIn  |0 (DE-588)124377483  |0 (DE-627)70661836X  |0 (DE-576)185833950  |4 aut 
245 1 0 |a Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma  |c Ronald Koschny, Daniel Gotthardt, Christiane Koehler, Dirk Jaeger, Wolfgang Stremmel and Tom M. Ganten 
264 1 |c 2013 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Published online: October 13, 2012 
500 |a Gesehen am 20.11.2018 
520 |a Objective: This study was performed to identify clinical predictors for better survival in patients with advanced hepatocellular carcinoma (HCC) under sorafenib treatment. Methods: Between December 2007 and January 2010, 46 patients with advanced HCC were treated with sorafenib until significant tumor progression or intolerable toxicity. We prospectively collected clinical baseline data as well as data on the incidence and severity of toxic side effects of sorafenib to be correlated with progression-free survival and overall survival (OS), respectively. Results: Only 26.1% (n = 12) of patients tolerated sorafenib without requiring dose reduction. The most frequent grade 3 toxicities were diarrhea (32.6%), hand-foot skin reaction (13.0%), fatigue (4.3%), and nausea/vomiting (2.2%). Eastern Cooperative Oncology Group performance status (p = 0.034) and portal vein infiltration (p = 0.021) significantly correlated with OS. Furthermore, we found a significant correlation between OS and appearance of grade 2 or 3 diarrhea with a median actuarial survival of 11.8 months (95% CI 6.9-16.6) compared to 4.2 months in patients with grade 0 or 1 diarrhea (95% CI 0.0-9.1; p = 0.009). In contrast, appearance of hand-foot skin reaction did neither correlate with progression-free survival nor with OS. Conclusion: Appearance of grade 2 or 3 diarrhea indicates a better OS of HCC patients undergoing sorafenib treatment. 
700 1 |a Gotthardt, Daniel  |d 1973-  |e VerfasserIn  |0 (DE-588)12903293X  |0 (DE-627)387885137  |0 (DE-576)297458027  |4 aut 
700 1 |a Jäger, Dirk  |d 1964-  |e VerfasserIn  |0 (DE-588)1032507535  |0 (DE-627)738505323  |0 (DE-576)380074125  |4 aut 
700 1 |a Stremmel, Wolfgang  |d 1952-  |e VerfasserIn  |0 (DE-588)142773638  |0 (DE-627)640118747  |0 (DE-576)33331560X  |4 aut 
700 1 |a Ganten, Tom M.  |d 1969-  |e VerfasserIn  |0 (DE-588)115539670  |0 (DE-627)69139010X  |0 (DE-576)289938899  |4 aut 
773 0 8 |i Enthalten in  |t Oncology  |d Basel : Karger, 1967  |g 84(2013), 1, Seite 6-13  |h Online-Ressource  |w (DE-627)300595409  |w (DE-600)1483096-6  |w (DE-576)098134302  |x 1423-0232  |7 nnas  |a Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma 
773 1 8 |g volume:84  |g year:2013  |g number:1  |g pages:6-13  |g extent:8  |a Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma 
856 4 0 |u http://dx.doi.org/10.1159/000342425  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.karger.com/Article/FullText/342425  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20181120 
993 |a Article 
994 |a 2013 
998 |g 115539670  |a Ganten, Tom M.  |m 115539670:Ganten, Tom M.  |d 50000  |e 50000PG115539670  |k 0/50000/  |p 6  |y j 
998 |g 142773638  |a Stremmel, Wolfgang  |m 142773638:Stremmel, Wolfgang  |d 910000  |d 910100  |e 910000PS142773638  |e 910100PS142773638  |k 0/910000/  |k 1/910000/910100/  |p 5 
998 |g 1032507535  |a Jäger, Dirk  |m 1032507535:Jäger, Dirk  |d 910000  |e 910000PJ1032507535  |k 0/910000/  |p 4 
998 |g 12903293X  |a Gotthardt, Daniel  |m 12903293X:Gotthardt, Daniel  |d 910000  |d 910100  |e 910000PG12903293X  |e 910100PG12903293X  |k 0/910000/  |k 1/910000/910100/ 
998 |g 124377483  |a Koschny, Ronald  |m 124377483:Koschny, Ronald  |d 910000  |d 910100  |e 910000PK124377483  |e 910100PK124377483  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN158386959X  |e 3032738660 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"person":[{"role":"aut","given":"Ronald","display":"Koschny, Ronald","family":"Koschny"},{"role":"aut","given":"Daniel","display":"Gotthardt, Daniel","family":"Gotthardt"},{"family":"Jäger","display":"Jäger, Dirk","given":"Dirk","role":"aut"},{"role":"aut","given":"Wolfgang","family":"Stremmel","display":"Stremmel, Wolfgang"},{"display":"Ganten, Tom M.","family":"Ganten","given":"Tom M.","role":"aut"}],"id":{"doi":["10.1159/000342425"],"eki":["158386959X"]},"name":{"displayForm":["Ronald Koschny, Daniel Gotthardt, Christiane Koehler, Dirk Jaeger, Wolfgang Stremmel and Tom M. Ganten"]},"physDesc":[{"extent":"8 S."}],"relHost":[{"part":{"year":"2013","pages":"6-13","issue":"1","text":"84(2013), 1, Seite 6-13","volume":"84","extent":"8"},"language":["eng"],"id":{"zdb":["1483096-6"],"issn":["1423-0232"],"eki":["300595409"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"300595409","disp":"Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinomaOncology","type":{"media":"Online-Ressource","bibl":"periodical"},"title":[{"title_sort":"Oncology","subtitle":"international journal of cancer research and treatment","title":"Oncology"}],"pubHistory":["21.1967 -"],"note":["Gesehen am 14.01.2019","Ungezählte Beil.: Supplement"],"origin":[{"publisherPlace":"Basel","dateIssuedDisp":"1967-","publisher":"Karger","dateIssuedKey":"1967"}]}],"recId":"158386959X","type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"2013"}],"note":["Published online: October 13, 2012","Gesehen am 20.11.2018"],"title":[{"title":"Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma","title_sort":"Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma"}]} 
SRT |a KOSCHNYRONDIARRHEAIS2013